



Fax completed prior authorization request form to 855-799-2554 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

Aetna Better Health®

All requested data must be provided. **Incomplete forms or forms without the chart notes will be returned**

Pharmacy Coverage Guidelines are available at www.aetnabetterhealth.com/florida/providers/provider-pharmacy

Opioids

Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Office notes, labs and medical testing relevant to request showing medical justification are required to support diagnosis

Member Information						
Member Name (first & last):		Date of Birth:	Gender:		Height:	
			<input type="checkbox"/> Male	<input type="checkbox"/> Female		
Member ID:		City:	State:		Weight:	
Prescribing Provider Information						
Provider Name (first & last):		Specialty:	NPI#	DEA#		
Office Address:		City:	State:	Zip Code:		
Office Contact:		Office Phone		Office Fax:		
Dispensing Pharmacy Information						
Pharmacy Name:		Pharmacy Phone:		Pharmacy Fax:		
Requested Medication Information						
Preferred Long Acting Agents:		<input type="checkbox"/> Morphine Sulfate ER tablets		<input type="checkbox"/> Fentanyl Patch (except half strengths)		
		<input type="checkbox"/> methadone		<input type="checkbox"/> oxymorphone extended release		
Non-Preferred Long Acting Agents:		Specify drug:				
Short Acting Opioid:		Specify drug:				
Are there any contraindications to formulary medications? (if yes, please specify):			<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> New request	
					<input type="checkbox"/> Continuation of therapy request	
Directions for Use:		Strength:		Dosage Form:		
		Quantity:	Day Supply:	Duration of Therapy/Use:		
Medication request is NOT for an FDA-approved, or compendia-supported diagnosis (circle one):		Diagnosis:		ICD-10 Code:		
Yes No						
What medication(s) have been tried and failed for this diagnosis? Please specify:						
Turn-Around Time for Review						
<input type="checkbox"/> Standard – (24 hours)		<input type="checkbox"/> Urgent – If waiting 24 hours for standard decision could seriously harm life, health, or ability to regain maximum function, you can ask for an expedited decision.				
		Signature: _____				
Clinical Information						
Pain is due to ONE of the following:		<input type="checkbox"/> Active Cancer	<input type="checkbox"/> Sickle Cell	<input type="checkbox"/> Palliative/End of life	<input type="checkbox"/> Hospice	<input type="checkbox"/> N/A
Will member be on both opioid AND benzodiazepine at same time?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Will Naloxone be provided/offered?		<input type="checkbox"/> Yes
				<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
Is request for opioid naïve member?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Is member opioid tolerant?		<input type="checkbox"/> Yes
				<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
Was non-pharmacologic therapy tried PRIOR to prescribing opioids (PT, exercise, CBT OR weight loss)?				<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Was non-opioid therapy tried PRIOR to prescribing opioids? (topical diclofenac NSAIDs, TCAs, and SNRIs OR anticonvulsants)				<input type="checkbox"/> Yes	<input type="checkbox"/> No	

Signed treatment plan addresses the following (check that apply):		<input type="checkbox"/> Realistic goals for pain AND function	<input type="checkbox"/> When treatment will be stopped	<input type="checkbox"/> Consequences of lost medication	<input type="checkbox"/> Consequences of obtaining controlled substances from other prescribers	<input type="checkbox"/> Member using ONE pharmacy
Was member advised of harm AND benefits before treatment AND periodically during treatment (increased risks of respiratory depression, combination use with BNZ, risks to others in household, cognitive limitations AND side effects)?					<input type="checkbox"/> Yes	<input type="checkbox"/> No
Will treatment be prescribed at lowest effective dose?					<input type="checkbox"/> Yes	<input type="checkbox"/> No
Will treatment be reviewed within 1-4 weeks of starting opioid therapy for CHRONIC pain AND with any DOSE-ESCALATION AND RE-EVALUATED every 3 months?					<input type="checkbox"/> Yes	<input type="checkbox"/> No
Was there review of state's PMP Drug Monitoring Program for controlled substances, with focus on opioid dosages OR dangerous combinations?					<input type="checkbox"/> Yes	<input type="checkbox"/> No
Was UDS reviewed prior to starting treatment?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Were results of UDS consistent with prescribed controlled substances?		<input type="checkbox"/> Yes <input type="checkbox"/> No
Is there evidence of substance use disorder?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was evidence-based treatment arranged (for example MAT)?		<input type="checkbox"/> Yes	<input type="checkbox"/> No <input type="checkbox"/> N/A
Is request for female of reproductive age?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was counseling provided about opioid use during pregnancy AND neonatal abstinence syndrome?		<input type="checkbox"/> Yes	<input type="checkbox"/> No <input type="checkbox"/> N/A
Additional Clinical Information						
<input type="checkbox"/> Long Acting Opioids						
Will member exceed 90 MME per day limit?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was documentation submitted to support exceeding recommended limit?		<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A
Was pain specialist consulted?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A	Is request for chronic pain? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Was treatment initiated with IR opioid for at least 2 weeks prior to considering ER/LA opioid?					<input type="checkbox"/> Yes	<input type="checkbox"/> No
Is request for oxymorphone ER?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was there inadequate response OR intolerance to 2 formulary LA opioids for 2 weeks?		<input type="checkbox"/> Yes <input type="checkbox"/> No
Is request for buprenorphine weekly patch?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Is there need for opioid with lower risk for abuse and a noted concern that member OR member's household is at risk for abuse AND diversion?		<input type="checkbox"/> Yes <input type="checkbox"/> No
Is request for non-formulary agent?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was there inadequate response OR intolerance to oxymorphone ER AND 2 formulary LA opioids for 2 weeks?		<input type="checkbox"/> Yes <input type="checkbox"/> No
Is request for abuse-deterrent product?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was there trial AND failure with buprenorphine patch for at least 2 weeks?		<input type="checkbox"/> Yes <input type="checkbox"/> No
				Is there NEED for abuse deterrent product AND concern that member OR household is at risk?		<input type="checkbox"/> Yes <input type="checkbox"/> No
Is request for methadone?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Is female member pregnant?		<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A
<input type="checkbox"/> Short Acting Opioids						
Will member exceed 90 MME per day limit?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was there documentation to support medical necessity of exceeding recommended MME, or day supply limit?		<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A
Is request for non-formulary short-acting agent?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was there inadequate response OR intolerance to 2 formulary short-acting opioids?		<input type="checkbox"/> Yes <input type="checkbox"/> No
Was documentation submitted supporting continued use of a SHORT ACTING AGENT beyond 30 days AND when used in combination with LONG-ACTING agent?					<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Acute Pain in Pediatric Members (< 18 years of age)						
Is request for acute pain (post-dental procedure)?			<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was a pain assessment completed? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has member AND their parent(s)/guardian(s) been screened for previous AND current opioid use?					<input type="checkbox"/> Yes	<input type="checkbox"/> No
Provider has checked state's PMP Drug Monitoring Program for controlled substances with focus on opioid dosages AND dangerous combinations?					<input type="checkbox"/> Yes	<input type="checkbox"/> No

Concomitant use with BNZ has been appropriately addressed if present?			<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
Combination therapy with APAP and NSAIDs were tried AND failed OR there are C/I present for use of both?				<input type="checkbox"/> Yes	<input type="checkbox"/> No
Opioid therapy will be used in combination with APAP and NSAIDs unless there are C/I present for use of both?				<input type="checkbox"/> Yes	<input type="checkbox"/> No
Member is NOT <12 years of age IF medication prescribed is codeine or tramadol (NOTE: use of these medications is C/I in children younger than 12 AND not recommended in those aged 12 – 17.)?			<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> N/A
Will prescription will be limited to 8 – 12 tablets?			<input type="checkbox"/> Yes	<input type="checkbox"/> No	
Will IR opioids will be prescribed, limited to lowest effective dose AND no quantity greater than expected pain duration that is severe enough to require opioids will be given (NOTE: 3 days or fewer is recommended by CDC)?				<input type="checkbox"/> Yes	<input type="checkbox"/> No
<input type="checkbox"/> Renewal ONLY					
Was there sustained improvement in Pain OR Function?		<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was tapering plan initiated to D/C treatment of current medication?	
		<input type="checkbox"/> Yes	<input type="checkbox"/> No	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Was UDS performed in past year?		<input type="checkbox"/> Yes		<input type="checkbox"/> No	
The state's PMP was reviewed AND verified (check that apply):		<input type="checkbox"/> Prescriptions from other providers	<input type="checkbox"/> Benzodiazepines use	<input type="checkbox"/> ER / LA use for acute pain	<input type="checkbox"/> UDS is consistent with prescribed controlled substances
Is dose ≥50 MME per day?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Did provider offer Naloxone to member?		<input type="checkbox"/> Yes
					<input type="checkbox"/> No
					<input type="checkbox"/> N/A
Is dose ≥90 MME per day?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Did provider refer member to Pain Specialist?		<input type="checkbox"/> Yes
					<input type="checkbox"/> No
					<input type="checkbox"/> N/A
Is there continued concomitant use of opioid AND BNZ?	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Was member counseled on FDA BBW dangers of concomitant use AND provider will prescribe at LOWEST effective dosage AND duration?		<input type="checkbox"/> Yes
					<input type="checkbox"/> No
					<input type="checkbox"/> N/A
Additional information the prescribing provider feels is important to this review. Please specify below or submit medical records					

Signature affirms that information given on this form is true and accurate and reflects office notes.	
Prescribing Provider's Signature: _____	Date: _____

Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Standard turnaround time is 24 hours. You can call to check the status of a request.

Florida Healthy Kids: 844-528-5815